Our Project Leader in in vitro pharmacology Méryl Roudaut will present his presentation entitled “A single procedure to generate functional hiPSCs-derived liver organoids – Towards an innovative tools suitable for drug screening” during the session: Early Stage Researcher Session I (Tuesday, November 22nd, 2022).

Abstract #165:

We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. With a non-invasive approach, hiPSCs can be generated from urine samples of patients and HLCs have been used to model cholesterol metabolism regulation, by the study of LDLR- and PCSK9-mediated autosomal dominant hypercholesterolemia (ADH) as well as PCSK9-mediated familial hypobetalipoproteinemia (FHBL). This model provides promising advantages with a direct link to the patient and with an unlimited source of HLCs. But like all models, there are limitations, mainly by the neonatal characteristic of HLCs lead to difficulties for pharmacological investigations.

Therefore, to overcome these burdens, we chose to 1. Differentiate hiPSCs into HLCs in an innovative 3D modified Hyaluronic Acid hydroscaffold, BIOMIMESYS® produces by HCS Pharma to enhance their maturation. 2. Adapt our 3D differentiation process to a 96-well format to make it compatible for drug screening. 3. Characterization of the 3D HLCs model by metabolism tests and compare to primary human hepatocyte (PHH). We gathered 3’ SRP data all along the differentiation process and RNAseq has been performed by comparing 2D and 3D differentiation conditions to characterize hiPSCs differentiation into liver organoïds. We observed an enhanced expression of most hepatic genes and genes expressed by non-parenchymal cells such as stellate cells. Immunofluorescence data confirmed the co-localization of albumin-positive hepatocytes, desmin-positive stellate cells and LYVE1-positive endothelial cells in liver organoïds. Finally, at a functional level, several CYP activities including CYP3A4 were detected at the basal level and successfully induced. Liver organoïds responded to pharmacological treatments as shown by their ability to accumulate lipids upon amiodarone treatment or uptake LDL-bodipy upon statin treatment.

Altogether, our development gave rise to functional liver organoïds generated with a unique and common procedure, in a process of automating for future high throughput screening.

Moreover, our Project Leader in in vitro pharmacology Véronique De Conto will present her poster entitled “In vitro microenvironment modifies the neurotoxic response of SH-SY5Y cells” (P-6a-8) during the session 6a:In vitro methods for safety testing of biopharmaceuticals/biotherapies/vaccines (Wednesday, November 23rd, 2022).


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.